Europe Human Microbiome Market 2018-2019 & Forecast to 2025 Featuring Enterome & Yakult Honsha

News provided by

May 22, 2019, 08:30 ET

DUBLIN, May 22, 2019 /PRNewswire/ -- The "Europe Human Microbiome Market to 2025 - Regional Analysis and Forecasts by Product, Disease, Application, and Country" report has been added to ResearchAndMarkets.com's offering.

The market is estimated to grow with a CAGR of 22.2% from 2018-2025.

The growth of the market is driven by the factors such alarming rise in non-communicable diseases (NCDS), rising efforts in the development of human microbiome based therapies and developments in genomics and sequencing techniques. Whereas, rigorous government regulations for advanced therapies and limited understanding is likely to have a negative impact on the growth of the market in the coming years.

Fecal microbiota transplantation (FMT) has developed as an effective treatment for C. difficile infection (CDI) refractory towards antibiotic therapy. The microbiota have important roles in the function of gastrointestinal tract and other aspects of human physiology, there is also growing interest in studying FMT for other clinical indications. The US Food and Drug Administration (FDA) has classified human stool as a biological agent and determined that its use in fecal microbiota transplantation (FMT) therapy and other research are regulated for the insurance of patient safety. With the use of FMT in the treatment of recurrent Clostridium difficile infection (RCDI), an investigational new drug (IND) permit is not required, but is strongly encouraged and may ultimately be required.

Some of the available data suggests that the use of fecal microbiota for the restoration of intestinal flora may be an effective therapy in the management of refractory C. difficile infection. According to the study, "Fecal Microbiota Transplant in Patients with Recurrent Clostridium Difficile Infection" published in Deutscher rzteverlag GmbH in 2016 concluded that FMT is a safe and effective treatment option for rCDI but FMT is available only in few centers in Germany. Thus clinical effectiveness of this therapy poses opportunities for the human microbiome treatment to grow in the European region.

Germany is anticipated to lead the adoptions of Human microbiome across the Europe region through the forecast period. Human microbiome is an emerging field in the country and the developments are being conducted widely in the country. The genome-wide association analysis study carried out in Germany was published in 2016. The study identifies variation in vitamin D receptor and other host factors influence the gut microbiota.

In addition, Germany invests considerably for innovation and development of new technologies and procedures. For instance, in April 2017, the German Science Council, has approved 53 million euros in funding for an Institute of Microbiota and Cancer Research in Tbingen. Thus, considering and analyzing the above mentioned factors, the human microbiome market is likely to grow with a significant growth rate in the coming future.

Key Topics Covered:

Part 1. Introduction

1.1 Scope of the Study

1.2 Report Guidance

Part 2. Europe Human Microbiome Market - Key Takeaways

Part 3. Europe Human Microbiome Market - Market Landscape

3.1 Overview

3.2 Market Segmentation

3.3 Pest Analysis

Part 4. Europe Human Microbiome Market - Key Market Dynamics

4.1 Key Market Drivers

4.1.1 Alarming Rise In Non-Communicable Diseases (Ncds)

4.1.2 Rising Efforts In the Development of Human Microbiome Based Therapies

4.1.3 Developments In Genomics and Sequencing Techniques

4.2 Key Market Restraints

4.2.1 Rigorous Government Regulations For Advanced Therapies

4.2.2 Limited Understanding Restricts the Growth of Market

4.3 Key Market Opportunities

4.3.1 Increasing Acceptance of Faecal Microbiota Transplantation

4.4 Future Trends

4.4.1 Recent Advances In Human Microbiome Drug Discovery

4.5 Impact Analysis

Part 5. Human Microbiome Market - Europe Analysis

5.1 Europe Human Microbiome Market Revenue Forecasts and Analysis

5.3 Market Positioning

5.4 Performance of Key Players

Enterome

Yakult Honsha Co., Ltd.

5.5 Expert Opinions

Part 6. Europe Human Microbiome Market Analysis - by Product

6.1 Overview

6.2 Europe Human Microbiome Market, by Product, 2017 & 2025 (%)

6.3 Europe Human Microbiome Market Revenue and Forecasts To 2025, by Product (US$ Mn)

6.4 Foods Market

6.5 Medical Food Market

6.6 Probiotics Market

6.7 Prebiotics Market

6.8 Drugs Market

6.9 Diagnostic Devices Market

6.10 Supplements Market

Part 7. Europe Human Microbiome Market Analysis - by Disease

7.1 Overview

7.2 Europe Human Microbiome Market, by Disease, 2017 & 2025 (%)

7.3 Europe Human Microbiome Market Revenue and Forecasts To 2025, by Disease (US$ Mn)

7.4 Diabetes Market

7.4.1 Overview

7.4.2 Europe Diabetes Market Revenue and Forecasts To 2025 (US$ Mn)

7.5 Cancer Market

7.6 Autoimmune Disorders Market

7.7 Obesity Market

7.8 Mental Disorders Market

7.9 Others Market

Part 8. Europe Human Microbiome Market Analysis - by Application

8.1 Overview

8.2 Europe Human Microbiome Market, by Application, 2017 & 2025 (%)

8.3 Europe Human Microbiome Market Revenue and Forecasts To 2025, by Application (US$ Mn)

8.4 Diagnostics Market

8.5 Therapeutics Market

Part 9. Europe Human Microbiome Market Revenue and Forecasts To 2025

Part 10. Human Microbiome Market -Industry Landscape

10.1 Overview

10.2 Growth Strategies In the Human Microbiome Market, 2015-2018

10.3 Organic Growth Strategies

10.4 Inorganic Growth Strategies

Part 11. Human Microbiome Market-Key Company Profiles

Enterome
MicroBiome Therapeutics, LLC
Rebiotix Inc.
Yakult Honsha Co., Ltd.
Osel Inc.
Vedanta Biosciences, Inc.
Metabiomics Corporate
Synthetic Biologics, Inc.
DuPont
BiomX Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/x2u05k

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets